Bahriye Aktas

Summary

Country: Germany

Publications

  1. ncbi Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Hufelandstrasse 55, D 45122 Essen, Germany
    Anticancer Res 33:329-36. 2013
  2. ncbi Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
    Volkmar Muller
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20241 Hamburg, Germany
    Breast Cancer Res 13:R71. 2011
  3. ncbi Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Breast Cancer Res 11:R46. 2009
  4. ncbi Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University of Essen, Hufelandstrase 55, 45122 Essen, Germany
    Gynecol Oncol 122:356-60. 2011
  5. ncbi Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Essen, Germany
    Int J Gynecol Cancer 21:822-30. 2011
  6. ncbi Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
    Tanja Fehm
    Department of Gynecology and Obstetrics, Calwer Strasse 7, University Hospital of Tuebingen, D 72076 Tuebingen, Germany
    Breast Cancer Res 11:R59. 2009
  7. ncbi Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study
    Oliver Hoffmann
    Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg Essen, Hufelandstrasse 55, D 45122 Essen, Germany
    Anticancer Res 31:3623-8. 2011
  8. ncbi HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
    Tanja Fehm
    Department of Gynecology and Obstetrics, University of Tubingen, Calwer Strasse 7, 72076, Tubingen, Germany
    Breast Cancer Res Treat 124:403-12. 2010
  9. ncbi Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies
    Mitra Tewes
    Department of Internal Medicine Cancer Research, University Hospital Essen, University of Duisburg Essen, 45122, Essen, Germany
    Breast Cancer Res Treat 115:581-90. 2009

Detail Information

Publications9

  1. ncbi Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Hufelandstrasse 55, D 45122 Essen, Germany
    Anticancer Res 33:329-36. 2013
    ..We correlated these findings with clinical parameters and evaluated their prognostic value with regard to overall survival (OS)...
  2. ncbi Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
    Volkmar Muller
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20241 Hamburg, Germany
    Breast Cancer Res 13:R71. 2011
    ..The aim of the study was to investigate whether serum concentrations of TIMP-1 and CAIX are associated with the detection of CTC in metastatic breast cancer...
  3. ncbi Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Breast Cancer Res 11:R46. 2009
    ....
  4. ncbi Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University of Essen, Hufelandstrase 55, 45122 Essen, Germany
    Gynecol Oncol 122:356-60. 2011
    ..It was the purpose of the present study (1) to reevaluate the ER/PR expression by CTCs and (2) to compare the hormone receptor status expression profile of CTCs with the primary tumor...
  5. ncbi Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Essen, Germany
    Int J Gynecol Cancer 21:822-30. 2011
    ..Results were compared with detection of DTC in BM...
  6. ncbi Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
    Tanja Fehm
    Department of Gynecology and Obstetrics, Calwer Strasse 7, University Hospital of Tuebingen, D 72076 Tuebingen, Germany
    Breast Cancer Res 11:R59. 2009
    ....
  7. ncbi Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study
    Oliver Hoffmann
    Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg Essen, Hufelandstrasse 55, D 45122 Essen, Germany
    Anticancer Res 31:3623-8. 2011
    ..The purpose of our study was to: i) analyze the presence of DTCs in the BM of breast cancer patients 2-10 years after first diagnosis of cancer, and ii) to study the effect of ibandronate on DTCs in those patients with DTC persistence...
  8. ncbi HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
    Tanja Fehm
    Department of Gynecology and Obstetrics, University of Tubingen, Calwer Strasse 7, 72076, Tubingen, Germany
    Breast Cancer Res Treat 124:403-12. 2010
    ..Therefore, it will be mandatory to correlate the assay-dependent HER2 status of CTCs to the clinical response on HER2-targeted therapies...
  9. ncbi Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies
    Mitra Tewes
    Department of Internal Medicine Cancer Research, University Hospital Essen, University of Duisburg Essen, 45122, Essen, Germany
    Breast Cancer Res Treat 115:581-90. 2009
    ..We analyzed circulating tumor cells (CTC) in blood of metastatic breast cancer patients (n = 42) and determined the ability of this method to predict therapy response...